ORKA Oruka Therapeutics, Inc. Common Stock
XNAS
90.33
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ORKA
$90.33
—
Key stats
$90.33
- 52-Week Range
- $25.23 – $115.52
- YTD
- +219.53%
- IV Rank (30D)
- 2.17
- Straddle Price
- $10.60
- P/C Vol Ratio
- 0.12
- Market Cap
- $5.3B
- Open
- $81.98
- Day Range
- $81.98 – $93.42
- Volume
- 1,942,847
- Prev Close
- $80.15
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.13% |
| Beta vs SPY | 0.89 |
| Cost of Equity (CAPM) | 9.58% (VRP-adj) |
| WACC | 9.61% |
| Volatility Risk Premium | +57.7pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -10.3% |
| Book / Price | 25.6% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $89.99 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $79.84 |
| Bollinger Width / SMA20 | 22.0% (drives anchor stability) |
| Net Debt | $-0.3B |
| Market Cap | $4B |
Peers used for multiples: AXSM, BTSG, GH, LLY, ROIV, RVMD, SYRE, TVTX
60-Day Conviction
68%
20-Day Fair Value
≈ by Nov 24, 2026
$91.51
α +1.3%
rank 84%
conviction
69%
40-Day Fair Value
≈ by Dec 23, 2026
$92.02
α +1.9%
rank 82%
conviction
60%
60-Day Fair Value
≈ by Jan 21, 2027
$92.37
α +2.3%
rank 80%
conviction
68%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | median 29.0× · 3 peers |
| Peer P/B | $316.81 | 18% | median 15.4× · 7 peers |
| Peer P/S | n/a | 0% | median 12.6× · 6 peers |
| Market Anchor (SMA50) | $89.99 | 37% | stability 40% (BB-width) |
| Options Expected (B-L 30d) | $79.71 | 46% | 23 strikes · skew +0.20 |
As of 2026-10-26 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $5.3B
- Employees
- 68
- List Date
- 2024-09-03
- CIK
- 0000907654
- Next Earnings
- 2026-11-11
- EPS Forecast
- ($0.68) (5 est.)
- Headquarters
- Menlo Park, CA
- Homepage
- https://www.orukatx.com
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and i…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | -32.65% | 21.08% | -5.79% |
| Feb | -- | -25.91% | 0.32% | -12.79% |
| Mar | -- | 3.53% | 45.59% | 24.56% |
| Apr | -- | 9.21% | 35.65% | 22.43% |
| May | -- | 8.62% | -6.47% | 1.07% |
| Jun | -- | -4.76% | 73.00% | 34.12% |
| Jul | -- | 15.17% | 2.85% | 9.01% |
| Aug | -- | 8.82% | -2.29% | 3.27% |
| Sep | -3.88% | 23.59% | -9.58% | 3.38% |
| Oct | 13.13% | 51.29% | 8.28%* | 24.23% |
| Nov | -20.08% | 14.93% | -- | -2.57% |
| Dec | -7.49% | 9.54% | -- | 1.02% |
| Total | -19.60% | 72.19% | 281.91% | 111.50% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $80.15
SMA 50: $89.57
SMA 200: $67.92
Current: $90.33
EMA 12: $80.88
EMA 26: $82.78
MACD: -1.9096 | Signal: 1.5021
BEARISH
ADX (14): 27.34
TREND
+DI: 33.26
−DI: 20.85
Momentum Oscillators
RSI (14): 60.75
NEUTRAL
Stoch %K: 75.22
Stoch %D: 68.24
Williams %R: -13.48
Volume & Volatility
BB Upper: $88.33
BB Lower: $71.96
OVERBOUGHT
OBV: 23,883,982
Vol SMA 20: 967,545
Vol ROC: 254.56%
ATR: $4.72
True Range: $13.27
HV 20: 64.3%
HV 30: 60.1%
HV 60: 52.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is my analysis of Oruka Therapeutics (ORKA) based on the provided data:
Executive Summary
Overall Assessment: NEUTRAL with confidence level 6/10
Key Drivers: Recent news headlines suggest a growing interest in ORKA's psoriasis drug, which could lead to increased investor enthusiasm. Technical indicators show a bullish trend, but momentum oscillators indicate a neutral market sentiment.
Primary Risks: High volatility, potential regulatory issues or setbacks in clinical trials, and competition from other pharmaceutical companies.
Investment Thesis: ORKA has the potential for significant growth as its psoriasis drug moves through clinical trials and prepares for FDA approval. However, the stock's high volatility and competitive industry pose risks to investors.
Recent News Sentiment Impact: The recent news headlines have a neutral sentiment, which is consistent with the overall assessment of NEUTRAL.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bullish
Support/Resistance Levels: The stock has resistance at $41.28 and support at $35.15, with a significant level of congestion between these two levels.
Momentum Signals:
- RSI interpretation: Neutral (66.46)
- MACD signal: Bullish (1.79 / Signal: 0.83 / Histogram: 0.96)
- Bollinger Bands position: Neutral (Price touching upper band)
Volume Analysis: Volume has been increasing, with a volume rate of change of 91.26%. This suggests growing interest in the stock.
News & Sentiment Analysis
Recent Headlines Summary:
- No recent headlines have had a significant impact on the stock's price.
Sentiment Assessment: Neutral (Average sentiment from news headlines)
Catalyst Identification: The upcoming clinical trial results and FDA approval could be potential catalysts for the stock.
Market Narrative: The market has been neutral, with no significant events or trends driving the stock's price.
Risk & Volatility Assessment
Beta Interpretation: ORKA is more volatile than the market (beta > 1.0).
Volatility Regime: High volatility (stock moves with market amplification)
Options Market Signals:
- IV rank: Low
- Put/call ratios: Bullish (15 calls vs 5 puts)
- Unusual activity: None
Downside Protection: Support levels at $35.15 and $29.01, with potential risk management considerations.
Market Context & Positioning
Sector Performance: ORKA is outperforming the sector average.
Institutional Activity: Institutional interest has been increasing, with a volume rate of change of 91.26%.
Correlation Analysis: ORKA is positively correlated with the market (R-squared interpretation).
Relative Valuation: The stock is trading within its recent range.
Key Levels & Action Items
Critical Price Levels:
- Support at $35.15
- Resistance at $41.28
Breakout/Breakdown Levels:
- Potential breakout above $41.28
- Potential breakdown below $35.15
Time-Sensitive Catalysts: Upcoming clinical trial results and FDA approval.
Risk Management: Consider stop-loss levels at $39.50 and position sizing considerations.
Conclusion
ORKA is a high-volatility stock with potential for significant growth as its psoriasis drug moves through clinical trials and prepares for FDA approval. The technical analysis suggests a bullish trend, but momentum oscillators indicate a neutral market sentiment. Recent news headlines have had a neutral impact on the stock's price. The risk assessment highlights the potential risks of high volatility, regulatory issues, and competition from other pharmaceutical companies.
Generated
News
All ORKA news →
Earnings History
1 of 1 under expected move
Avg Expected Move
11.75%
Avg Actual Move
0.44%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-08-10 | unknown | 11.75% | 0.44% | 0.04x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ORKA Options Activity & IV Rank
ORKA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 57.0%
7-DTE IV: —
Expected Move: $10.60
7-DTE Move: $10.60
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 1,259
Put Volume: 151
P/C Volume: 0.12
BULLISH
Call OI: 3,168
Put OI: 121
P/C OI: 0.038
Total OI: 3,289
ATM Options Pricing
ATM Call: $5.65
ATM Put: $4.95
Call %: 6.3%
Put %: 5.5%
Chain Summary
Chain Volume: 2,368
Chain OI: 8,591
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 76th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
76%
vs own history
GEX tilt
+0.28
OI-weighted, today
Vanna tilt
-0.14
δ-sensitivity to IV
Charm tilt
+0.10
δ-decay vs time
? What is this?
· 14 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 56.3% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)2.2LowOct 26
Straddle Price (30 DTE)$10.60Oct 26
Beta Analysis
Risk Metrics
Beta: 1.4195
Alpha: 124.97%
Correlation: 0.2619
R-Squared: 6.9%
Stock Volatility: 69.1%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
ORKA Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 54,318,584 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$18.28M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $15.07M | 82.46% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $2.27M | 12.44% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $456.82K | 2.50% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $390.20K | 2.13% | 2026-06-30 |
| 5 | Belvedere Trading LLC | $76.14K | 0.42% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $9.52K | 0.05% | 2026-06-30 |
5 filers$15.07M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $11.12M | 73.74% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $1.91M | 12.69% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $1.05M | 6.94% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $923.15K | 6.12% | 2026-06-30 |
| 5 | Belvedere Trading LLC | $76.14K | 0.51% | 2026-06-30 |
ORKA Insider Trading (Form 4)
Latest: 2026-10-20Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Paul T Quinlan | General Counsel | Mixed | — | $43.16 | -$636.5K | EDGAR |
| 2026-10-15 | Joana Goncalves | Chief Medical Officer | Mixed | — | $41.06 | -$472.4K | EDGAR |
| 2026-10-13 | Arjun Agarwal | Senior Vice President, Finance | Mixed | — | $48.14 | -$649.0K | EDGAR |
| 2026-10-02 | Lawrence Otto Klein | Chief Executive Officer | Mixed | — | $45.71 | -$1.90M | EDGAR |
| 2026-09-21 | Arjun Agarwal | Senior Vice President, Finance | Sell (S) | −533 | $95.75 | -$51.0K | EDGAR |
| 2026-09-21 | Paul T Quinlan | General Counsel | Mixed | — | $50.72 | -$858.4K | EDGAR |
| 2026-09-15 | Lawrence Otto Klein | Chief Executive Officer | Sell (S) | −2,452 | $95.71 | -$234.7K | EDGAR |
| 2026-09-15 | Laura Lee Sandler | Chief Operating Officer | Sell (S) | −906 | $95.71 | -$86.7K | EDGAR |
| 2026-09-15 | Paul T Quinlan | General Counsel | Sell (S) | −1,039 | $95.71 | -$99.4K | EDGAR |
| 2026-09-15 | Joana Goncalves | Chief Medical Officer | Mixed | −947 | $52.54 | -$682.9K | EDGAR |
| 2026-09-15 | Arjun Agarwal | Senior Vice President, Finance | Mixed | −560 | $55.25 | -$775.8K | EDGAR |
| 2026-09-01 | Laura Lee Sandler | Chief Operating Officer | Mixed | — | $49.81 | -$420.1K | EDGAR |
| 2026-09-01 | Lawrence Otto Klein | Chief Executive Officer | Mixed | — | $49.82 | -$6.30M | EDGAR |
| 2026-08-25 | Larry Todd Edwards | Chief Commercial Officer | Award (A) | +100,000 | — | EDGAR | |
| 2026-08-17 | Joana Goncalves | Chief Medical Officer | Mixed | — | $59.58 | -$731.6K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ORKA Insider Holdings
11 insiders · @ $90.33
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | VHCP Management EG, LLC | 10%+ Owner | 4,044,684 | $365.36M | $9.85M | 1 | 2025-02-27 |
| 2 | Tomas Kiselak | Director | 2,573,308 | $232.45M | $0 | 1 | 2025-09-19 |
| 3 | Peter Evan Harwin | Director | 1,131,954 | $102.25M | -$1.50B | 2 | 2026-07-01 |
| 4 | Lawrence Otto Klein | Chief Executive Officer | 923,328 | $83.40M | -$9.40M | 7 | 2026-10-02 |
| 5 | Fairmount Healthcare Fund II L.P. | Director | 638,614 | $57.69M | $0 | 2 | 2026-06-03 |
| 6 | Laura Lee Sandler | Chief Operating Officer | 235,478 | $21.27M | -$1.94M | 10 | 2026-09-15 |
| 7 | Larry Todd Edwards | Chief Commercial Officer | 100,000 | $9.03M | $0 | 1 | 2026-08-25 |
| 8 | Carl Dambkowski | Director | 51,326 | $4.64M | -$8.65M | 5 | 2026-06-12 |
| 9 | Paul T Quinlan | General Counsel | 37,095 | $3.35M | -$7.47M | 8 | 2026-10-20 |
| 10 | Joana Goncalves | Chief Medical Officer | 32,671 | $2.95M | -$5.07M | 13 | 2026-10-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ORKA Board & Officers
As of SEC filings through Oct 20, 2026Directors 10
- Carl Dambkowski · since Aug 29, 2024
- Fairmount Funds Management LLC (entity) · since Aug 29, 2024
- Fairmount Healthcare Co-Invest III L.P. (entity) · since Aug 29, 2024
- Fairmount Healthcare Fund II L.P. (entity) · since Aug 29, 2024
- Kristine M Ball · since Aug 29, 2024
- Lawrence Otto Klein · since Aug 29, 2024
- Peter Evan Harwin · since Aug 29, 2024
- Samarth Kulkarni · since Aug 29, 2024
- Tomas Kiselak · since Aug 29, 2024
- Christopher Nathan Martin · since Dec 11, 2025
Officers 6
- Lawrence Otto Klein · Chief Executive Officer · listed since Jan 2025
- Arjun Agarwal · Senior Vice President, Finance · listed since Jan 2025
- Laura Lee Sandler · Chief Operating Officer · since Jul 1, 2025
- Joana Goncalves · Chief Medical Officer · since Aug 29, 2024
- Larry Todd Edwards · Chief Commercial Officer · since Aug 24, 2026
- Paul T Quinlan · General Counsel · listed since Jan 2025
10% owners 5
- Fairmount Funds Management LLC (entity) · since Aug 29, 2024
- Fairmount Healthcare Co-Invest III L.P. (entity) · since Aug 29, 2024
- Fairmount Healthcare Fund II L.P. (entity) · since Aug 29, 2024
- Peter Evan Harwin · since Aug 29, 2024
- Tomas Kiselak · since Aug 29, 2024
Changes in the last 10 years (71)
| Aug 24, 2026 | Larry Todd Edwards became Chief Commercial Officer |
| Dec 11, 2025 | The company announced the departure of Cameron Turtle from the board in an SEC filing |
| Dec 11, 2025 | Christopher Nathan Martin became a director |
| Jul 1, 2025 | Laura Lee Sandler became Chief Operating Officer |
| Feb 27, 2025 | Nimish P Shah first listed as a 10% owner in an SEC filing |
| Feb 27, 2025 | Bong Y Koh first listed as a 10% owner in an SEC filing |
| Feb 10, 2025 | Venrock Healthcare Capital Partners III, L.P. became a 10% owner |
| Feb 10, 2025 | Venrock Healthcare Capital Partners EG, L.P. became a 10% owner |
| Feb 10, 2025 | VHCP Management III, LLC became a 10% owner |
| Feb 10, 2025 | VHCP Management EG, LLC became a 10% owner |
| Feb 10, 2025 | VHCP Co-Investment Holdings III, LLC became a 10% owner |
| Jan 24, 2025 | Paul T Quinlan listed as General Counsel (previously General Counsel and Secretary) in SEC filings |
| Jan 24, 2025 | Lawrence Otto Klein listed as Chief Executive Officer (previously President and CEO) in SEC filings |
| Jan 24, 2025 | Arjun Agarwal listed as Senior Vice President, Finance (previously SVP, Finance and Treasurer) in SEC filings |
| Aug 30, 2024 | Jacob Ma-Weaver reported in an SEC filing no longer being a director |
| Aug 30, 2024 | Jacob Ma-Weaver reported in an SEC filing no longer being a 10% owner |
| Aug 29, 2024 | Tomas Kiselak became a director |
| Aug 29, 2024 | Tomas Kiselak became a 10% owner |
| Aug 29, 2024 | The company announced the departure of Robert E Conway from the board in an SEC filing |
| Aug 29, 2024 | The company announced the departure of Robert E Conway from the board in an SEC filing |
| Aug 29, 2024 | The company announced the departure of Linda Grais from the board in an SEC filing |
| Aug 29, 2024 | The company announced the departure of James P Flynn from the board in an SEC filing |
| Aug 29, 2024 | The company announced the departure of Anders D Hove from the board in an SEC filing |
| Aug 29, 2024 | Samarth Kulkarni became a director |
| Aug 29, 2024 | Peter Evan Harwin became a director |
| Aug 29, 2024 | Peter Evan Harwin became a 10% owner |
| Aug 29, 2024 | Paul T Quinlan became General Counsel and Secretary |
| Aug 29, 2024 | Lawrence Otto Klein became a director |
| Aug 29, 2024 | Lawrence Otto Klein became President and CEO |
| Aug 29, 2024 | Kristine M Ball became a director |
| Aug 29, 2024 | Joana Goncalves became Chief Medical Officer |
| Aug 29, 2024 | Fairmount Healthcare Fund II L.P. became a director |
| Aug 29, 2024 | Fairmount Healthcare Fund II L.P. became a 10% owner |
| Aug 29, 2024 | Fairmount Healthcare Co-Invest III L.P. became a director |
| Aug 29, 2024 | Fairmount Healthcare Co-Invest III L.P. became a 10% owner |
| Aug 29, 2024 | Fairmount Funds Management LLC became a director |
| Aug 29, 2024 | Fairmount Funds Management LLC became a 10% owner |
| Aug 29, 2024 | Carl Dambkowski became a director |
| Aug 29, 2024 | Cameron Turtle became a director |
| Aug 29, 2024 | Arjun Agarwal became SVP, Finance and Treasurer |
| Jul 2, 2024 | Janus Henderson Group Plc became a 10% owner |
| Jul 2, 2024 | Janus Henderson Biotech Innovation Master Fund Ltd became a 10% owner |
| Feb 2, 2024 | The company announced the departure of Raymond L. Woosley from the board in an SEC filing |
| Feb 2, 2024 | The company announced the departure of Daniel J Mitchell from the board in an SEC filing |
| Jan 31, 2024 | Robert E Conway first listed as a director in an SEC filing |
| Jan 31, 2024 | Jacob Ma-Weaver first listed as a 10% owner in an SEC filing |
| Dec 15, 2022 | James P Flynn became a director |
| Jun 21, 2022 | Jacob Ma-Weaver first listed as a director in an SEC filing |
| May 10, 2021 | C. Jeffrey Dekker became Chief Financial Officer |
| Feb 28, 2018 | Venrock Healthcare Capital Partners LP reported in an SEC filing no longer being a 10% owner |
| Feb 28, 2018 | Venrock Healthcare Capital Partners II, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 28, 2018 | VHCP Management, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 28, 2018 | VHCP Management II, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 28, 2018 | VHCP Co-Investment Holdings, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 28, 2018 | VHCP Co-Investment Holdings II, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 28, 2018 | Bong Y Koh reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | Scott D Sandell reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | Ravi Viswanathan reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | Peter W. Sonsini reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | Peter J Barris reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | New Enterprise Associates 15, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | Nea 15 Gp, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | NEA Partners 15, L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | Joshua Makower reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | Jon Sakoda reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | Growth Equity Opportunities IV, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | Forest Baskett reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | David M Mott reported in an SEC filing no longer being a 10% owner |
| Feb 27, 2018 | Anthony A. Florence Jr. reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2017 | Anders D Hove no longer listed as a 10% owner in SEC filings |
| Feb 21, 2017 | Anders D Hove first listed as a director in an SEC filing |
Not reported recently (14)
- Bong Y Koh · Last reported as a 10% owner in an SEC filing dated Feb 27, 2025
- Nimish P Shah · Last reported as a 10% owner in an SEC filing dated Feb 27, 2025
- VHCP Management III, LLC · Last reported as a 10% owner in an SEC filing dated Feb 27, 2025
- Venrock Healthcare Capital Partners III, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 27, 2025
- VHCP Co-Investment Holdings III, LLC · Last reported as a 10% owner in an SEC filing dated Feb 27, 2025
- VHCP Management EG, LLC · Last reported as a 10% owner in an SEC filing dated Feb 27, 2025
- Venrock Healthcare Capital Partners EG, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 27, 2025
- Janus Henderson Group Plc · Last reported as a 10% owner in an SEC filing dated Aug 20, 2024
- Janus Henderson Biotech Innovation Master Fund Ltd · Last reported as a 10% owner in an SEC filing dated Aug 20, 2024
- Michael R Bristow · Last reported as a director in an SEC filing dated Jan 30, 2024
- Thomas A Keuer · Last reported as Chief Operating Officer in an SEC filing dated Dec 9, 2022
- C. Jeffrey Dekker · Last reported as Chief Financial Officer in an SEC filing dated Dec 9, 2022
- Christopher David Ozeroff · Last reported as S.V.P., General Counsel in an SEC filing dated Dec 16, 2021
- Brian L. Selby · Last reported as VP, Finance in an SEC filing dated Dec 23, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ORKA Proposed Insider Sales (Form 144)
Latest: 2026-10-15
? Form 144 Guide
Last 30d:
3 filings
· $4.5M notice value
· Last 90d:
7 filings
· $19.7M notice value
· 5 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
LAWRENCE KLEIN (2, $9.0M) · PAUL QUINLAN (1, $7.7M) · JOANA GONCALVES (1, $1.6M) · Arjun Agarwal (2, $872K) · LAURA SANDLER (1, $463K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 | JOANA GONCALVES | Officer | 21,000 | $1.61M | 2026-10-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-13 | Arjun Agarwal | Officer | 9,999 | $821.0K | 2026-10-12 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-01 | LAWRENCE KLEIN | Director, Officer | 25,000 | $2.08M | 2026-10-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-21 | Arjun Agarwal | Officer | 533 | $50.6K | 2026-09-21 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-01 | LAURA SANDLER | Officer | 5,000 | $463.1K | 2026-09-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-01 | LAWRENCE KLEIN | Director, Officer | 75,000 | $6.95M | 2026-09-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-14 | PAUL QUINLAN | Officer | 71,000 | $7.68M | 2026-08-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-15 | JOANA GONCALVES | Officer | 21,000 | $1.84M | 2026-07-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-13 | Arjun Agarwal | Officer | 28,588 | $2.48M | 2026-07-13 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-01 | Fairmount Healthcare Fund II L.P. | Director, 10% Stockholder | 3,553,410 | $300.01M | 2026-07-01 | Goldman Sachs & Co. LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
73 ETFs hold ORKA
25 shown · $731.62M total exposure · 0.16% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $158.3M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.33% | $137.3M | $10.4B | 2026-10-23 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.14% | $101.5M | $74.6B | 2026-10-23 |
| 4 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.03% | $55.8M | — | 2026-09-30 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.06% | $53.4M | — | 2026-09-30 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.28% | $37.7M | $13.7B | 2026-10-23 |
| 7 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.34% | $35.9M | $10.7B | 2026-10-23 |
| 8 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.07% | $31.1M | — | 2026-09-30 |
| 9 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.14% | $24.4M | — | 2026-09-30 |
| 10 | CGMM Capital Group U.S. Small and Mid Cap ETF | Capitalgroup | 0.42% | $14.9M | $3.5B | 2026-10-23 |
| 11 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.06% | $13.7M | — | 2026-05-31 |
| 12 | VHT Vanguard Health Care ETF | Vanguard | 0.04% | $9.8M | — | 2026-09-30 |
| 13 | PTH Invesco Dorsey Wright Healthcare Momentum ETF | Nport | 2.74% | $6.4M | — | 2026-07-31 |
| 14 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.09% | $6.1M | $6.6B | 2026-10-23 |
| 15 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $6.0M | $96.5B | 2026-10-23 |
| 16 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.93% | $5.3M | — | 2026-10-26 |
| 17 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $5.0M | — | 2026-10-23 |
| 18 | FTXH First Trust Nasdaq Pharmaceuticals ETF | First Trust | 0.42% | $4.8M | $1.1B | 2026-10-23 |
| 19 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.27% | $4.6M | — | 2026-09-30 |
| 20 | USVM VictoryShares US Small Mid Cap Value Momentum ETF | Nport | 0.25% | $4.4M | — | 2026-06-30 |
| 21 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $3.5M | — | 2026-09-30 |
| 22 | FSMD Fidelity Small-Mid Multifactor ETF | Fidelity | 0.13% | $3.1M | $2.5B | 2026-10-23 |
| 23 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.17% | $3.1M | — | 2026-10-23 |
| 24 | SBIO ALPS Medical Breakthroughs ETF | Nport | 1.80% | $2.9M | — | 2026-05-31 |
| 25 | FFSM Fidelity Fundamental Small-Mid Cap ETF | Nport | 0.17% | $2.6M | — | 2026-07-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.02
TTM Revenue
—
TTM Net Income
$-115.23M
TTM Op. Cash Flow
$-100.92M
Quarterly figures (7 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-34.87M | $-0.55 | $-33.15M |
| Q1 '26 | 2026-03-31 | — | $-31.82M | $-0.48 | $-23.58M |
| Q4 '25 | 2025-12-31 | — | $-24.50M | $-0.45 | $-22.59M |
| Q3 '25 | 2025-09-30 | — | $-24.04M | $-0.55 | $-21.60M |
| Q2 '25 | 2025-06-30 | — | $-19.33M | $-0.46 | $-23.14M |
| Q1 '25 | 2025-03-31 | — | $-21.00M | $-0.40 | $-20.87M |
| Q3 '24 | 2024-09-30 | — | $-21.94M | $-1.46 | — |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-10
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
4.40
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-10.3%
ROA
-10.1%
Div Yield
0.00%
FCF Yield
-2.06%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$4.91B
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.78M
SI % of Float
14.65%
Days to Cover
6.32
Short Vol Ratio
67.6%
Free Float
53.08M
Float %
80.2%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-22